Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
In this prospective randomized study for patients with newly diagnosed acute promyelocytic
leukemia, patients will be randomized (1:1) into two groups which receive retinoic acid and
arsenic trioxide based treatment versus retinoic acid and chemotherapy based regimen.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborators:
First Affiliated Hospital of Guangxi Medical University First Affiliated Hospital of Zhejiang University First Affiliated Hospital, Sun Yat-Sen University First Hospital of China Medical University Guangdong Provincial People's Hospital Institute of Hematology & Blood Diseases Hospital Nanfang Hospital of Southern Medical University Ningbo No. 1 Hospital Peking University People's Hospital Qilu Hospital of Shandong University Shandong Provincial Hospital Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Southwest Hospital, China Tang-Du Hospital The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Soochow University The First Affiliated Hospital with Nanjing Medical University The Second Affiliated Hospital of Dalian Medical University Tongji Hospital Union hospital of Fujian Medical University West China Hospital Wuhan Union Hospital, China